The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

GW Pharmaceuticals PLC

Nasdaq: GWPH
Last

(U.S.) $82.53

Today's change+1.51 +1.86%
Updated May 2 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

GW Pharmaceuticals PLC

Nasdaq: GWPH
Last

(U.S.) $82.53

Today's change+1.51 +1.86%
Updated May 2 4:00 PM -4GMT. Delayed by at least 15 minutes.

GW Pharmaceuticals PLC crosses above 20-day moving average

GW Pharmaceuticals PLC closed up sharply Monday, rallying (U.S.)$1.51 or 1.86% to (U.S.)$82.53 and crossing above its 20-day moving average. Shares have lost 2.06% over the last five days, but have gained 18.85% over the last year to date. This security has underperformed the S&P 500 by 23.10% during the last year.

Key company metrics

  • Open(U.S.) $81.92
  • Previous close(U.S.) $81.02
  • High(U.S.) $82.65
  • Low(U.S.) $79.22
  • Bid / Ask(U.S.) $79.22 / (U.S.) $82.48
  • YTD % change+18.85%
  • Volume292,163
  • Average volume (10-day)424,899
  • Average volume (1-month)587,477
  • Average volume (3-month)619,345
  • 52-week range(U.S.) $35.83 to (U.S.) $133.98
  • Beta--
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$4.06
Updated May 2 4:00 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX0.62%Sector:Industry:

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue4696
Total other revenue--------
Total revenue4696
Gross profit3586
Total cost of revenue1111
Total operating expense25243316
Selling / general / administrative4534
Research & development24252115
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-21-19-25-9
Interest income (expense), net non-operating0000
Gain (loss) on sale of assets--------
Other--------
Income before tax-21-19-25-9
Income after tax-18-12-21-7
Income tax, total-3-6-3-2
Net income-18-12-21-7
Total adjustments to net income--------
Net income before extra. items-18-12-21-7
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-18-12-21-7
Inc. avail. to common incl. extra. items-18-12-21-7
Diluted net income-18-12-21-7
Dilution adjustment--------
Diluted weighted average shares261261251237
Diluted EPS excluding extraordinary itemsvalue per share-0.07-0.05-0.09-0.03
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.07-0.05-0.09-0.03